TABLE 2.
Comparison of the designed AMPs in this study.
| Peptide | MIC/MBC A. baumannii 17978 (μg/mL) | Hemolysis (%) at 256 μg/mL | HEK293 IC50 (μg/mL) | Half-life in plasma (h) | Selectivity index (SI)a | |
|
|
||||||
| 1 h | 24 h | |||||
| pepD2 | 8/8 | 9.6 | 29.1 | 37.3 | 23.08 | 4.7 |
| pepD3 | 8/8 | 3.15 | 49.5 | 68.1 | 19.13 | 8.5 |
| pepV2 | 16/32 | 0.31 | ||||
| pepI2 | 4/4 | 0.27 | 68.5 | 66.8 | 10.86 | 16.7 |
| pepR2 | 8/8 | 105.65 | ||||
| pepO2 | 8/8 | 0.23 | ||||
| pepdD2 | 8/8 | 2.9 | 40.2 | 20.6 | 289.6 | 2.6 |
| pepD2M | >32/x | 93.63 | ||||
| pepD2P | >32/x | 83.45 | ||||
| pepD2S | >32/x | 60.70 | ||||
| pepD3O | 8/8 | 86.03 | ||||
| pepD3H | 8/8 | 54.07 | ||||
| pepD3B | 8/8 | 7.89 | ||||
“x” indicates that the MBC could not be measured due to an MIC > 32 μg/mL. Only four peptides with a low MBC and low hemolysis had their cytotoxicity and half-life measured. aSI is equal to the HEK293 IC50 (24-h treatment) divided by MBC.